The pharmaceutical industry is moving too fast with AI agents without building the right foundation first. More than 450 executives from over 100 leading life sciences organizations gathered at Axtria Ignite 2026 in Princeton, New Jersey, to confront a counterintuitive reality: before companies build more autonomous AI systems, they need to fix the underlying data infrastructure that makes those systems trustworthy.

Why Are So Many AI Agent Deployments Failing in Pharma?

The numbers paint a sobering picture. Roughly 73% of biopharma companies still report significant data quality issues, according to Axtria founder and CEO Jaswinder "Jassi" Chadha. Even more striking, 89% of AI pilots never make it to production, and trust in AI systems has actually declined from 61% in 2019 to 53% today, even as the industry races toward deploying an estimated 100,000-plus AI agents.

Against a pharmaceutical accuracy standard of 99.5%, this gap between ambition and execution represents a critical vulnerability. The problem isn't the AI models themselves; it's what sits beneath them. "Before you build the agent, fix the foundation first," Chadha stated. "The companies that will lead the agentic era are not the ones who moved fastest; they are the ones who built them with trust."

What Does a Trustworthy AI Agent Foundation Actually Require?

Chadha outlined four essential components that must be in place before deploying autonomous AI systems at scale in pharmaceutical environments:

• AI-Ready Data Supply Chain: Clean, well-organized data that flows reliably into AI systems without gaps or inconsistencies that could lead to incorrect decisions.
• Semantic Layer for Agent Accuracy: A translation layer that ensures the AI agent understands the meaning and context of data, not just the raw numbers.
• Software Guardrails for Deterministic Precision: Hard boundaries that force the agent to make decisions with mathematical certainty in high-stakes situations, rather than probabilistic guesses.
• Governance Framework for Digital Workers at Scale: Clear policies and audit trails that treat AI agents like new employees who must earn trust through validation, not receive it automatically.

The framing is deliberate. Agents, in Chadha's view, are new hires who must prove themselves through rigorous testing and auditing before being trusted with critical business decisions.

One senior leader at a major pharmaceutical company shared a practical unlock: making clear to her team that AI was designed to elevate marketers rather than replace them. Adoption subsequently climbed to over 90%. "This is not an AI revolution. It's a people revolution," she noted during the closing mainstage session.

How Are Leading Companies Proving AI Agent ROI?

The conference featured candid discussions between Axtria co-founder and CTO Navdeep "Navi" Chadha and senior leaders from Thermo Fisher Scientific and Quest Diagnostics. A recurring theme emerged: change management is the actual work, not a footnote in a business case. One senior digital leader emphasized that "change management and adoption cannot be the 45th slide in a 30-page deck at the business case approval".

Quest Diagnostics received the Axtria Bedrock Honor for implementing an AI-powered sales force alignment solution across 34 different role types and approximately 1,300 field employees, described as one of the most complex sales force alignments in healthcare. The company's success demonstrates that when the foundation is solid, AI agents can handle genuinely intricate, real-world business problems.

Axtria also recognized transformation leaders from Bristol Myers Squibb, GSK, and Biogen with its annual Ignite Leadership Awards, honoring executives driving enterprise-wide AI transformations and bringing multiple disciplines together to strengthen the foundation of AI deployment.

What's the Broader Shift Happening in Agentic AI?

The pharmaceutical industry's caution reflects a larger maturation in how enterprises think about autonomous AI systems. Agentic AI represents a fundamental shift from reactive systems that answer questions to autonomous systems that can perceive their environment, make decisions, and take actions to achieve specific goals without constant human intervention.

Unlike traditional generative AI, which produces an output in response to a prompt, agentic AI systems can break down complex goals into multi-step plans, execute those steps, and adapt based on new information. They can interact with external tools, databases, and APIs, and modify their approach in response to outcomes.

Three core components power these systems: the agent itself, powered by a large language model (LLM) or other AI engine that provides reasoning; tools and connectors that allow the agent to access data and external systems; and protocols and frameworks that guide how agents interact and stay within human-defined boundaries.

Across retail, healthcare, and other industries, a new discipline has emerged: harness engineering. Rather than focusing on what the agent knows, harness engineers design the execution environment around autonomous agents, determining what the agent can do, how its actions are verified, and what happens at the boundary of its confidence.

The message from Axtria's conference is clear: the pilot era for AI agents is over. The real work now is building the infrastructure, governance, and trust mechanisms that allow these systems to operate reliably at scale. Companies that invest in that foundation first will lead the agentic era. Those that skip it will join the 89% of AI projects that never reach production.